Showing results (31-40 of 180) with videos related to

Sort By:
Pageof 18
Epigenetics|February 14, 2018
An epigenomic approach to identifying differential overlapping and cis-acting lncRNAs in cisplatin-resistant cancer cellsOlga Vera, Carlos Rodriguez-Antolin, Javier de Castro, et al.
The Journal of Clinical Endocrinology and Metabolism|April 24, 2008
Hyperinsulinemia induces insulin resistance on glucose and lipid metabolism in a human adipocytic cell line: paracrine interaction with myocytesSonia Fernández-Veledo, Iria Nieto-Vazquez, Javier de Castro, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 18, 2008
Molecular biology of pancreatic cancerCristóbal Belda-Iniesta, Immaculada Ibáñez de Cáceres, Jorge Barriuso, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 29, 2006
Molecular biology of malignant gliomasCristóbal Belda-Iniesta, Javier de Castro Carpeño, Enrique Casado Sáenz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 28, 2022
A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel studyDolores Isla, Enriqueta Felip, Pilar Garrido, et al.
Current Medical Research and Opinion|October 6, 2011
An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancerMark J C Nuijten, Rick Aultman, Javier de Castro Carpeño, et al.
Cancer Investigation|April 30, 2008
Erythrocyte and platelet phospholipid fatty acids as markers of advanced non-small cell lung cancer: comparison with serum levels of sialic acid, TPS and Cyfra 21-1Javier de Castro, Marina C Rodríguez, Vicenta S Martínez-Zorzano, et al.
Anti-Cancer Drugs|April 9, 2009
Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastasesJavier de Castro-Carpeño, María Sereno Moyano, Enrique Casado Sáenz, et al.
International Journal of Oncology|February 21, 2012
ERCC1 and topoisomerase I expression in small cell lung cancer: prognostic and predictive implicationsMaria Sereno, Paloma Cejas, Víctor Moreno, et al.
Clinicoeconomics and Outcomes Research : CEOR|January 25, 2017
Costs of adverse events associated with erlotinib or afatinib in first-line treatment of advanced EGFR-positive non-small cell lung cancerDolores Isla, Javier De Castro, Oscar Juan, et al.
Pageof 18